This page analyzes whether Parkinson's disease (PD) research funding aligns with the evidence base for therapeutic approaches. By comparing NIH funding levels to the evidence scores from the PD Therapeutic Scorecard, we can identify:
Funding Data: NIH research funding estimates are derived from published analyses of NIH RePORTER data, NINDS budget documents, and peer-reviewed funding analyses. Figures represent annual funding averages across FY2019-2024.
Evidence Scores: Taken from the PD Therapeutic Scorecard, which uses a 7-dimension rubric (0-70 points) assessing mechanistic clarity, clinical evidence, delivery feasibility, safety, combinability, timeline, and root-cause targeting.
Funding-to-Evidence Ratio: Calculated as normalized funding / normalized evidence score. A ratio >1.2 suggests over-funding; <0.8 suggests under-funding.
| Rank | Therapeutic Approach | NIH Funding ($M/yr) | Evidence Score (0-70) | F/E Ratio | Assessment |
|---|---|---|---|---|---|
| 1 | Levodopa/Carbidopa/Entacapone | $45 | 59 | 0.76 | Under-funded |
| 2 | MAO-B Inhibitors | $35 | 58 | 0.60 | Under-funded |
| 3 | COMT Inhibitors | $25 | 56 | 0.45 | Under-funded |
| 4 | Dopamine Agonists | $40 | 55 | 0.73 | Under-funded |
| 5 | Deep Brain Stimulation | $55 | 51 | 1.08 | Balanced |
| 6 | Exercise & Lifestyle | $18 | 57 | 0.32 | Under-funded |
| 7 | GLP-1 Agonists | $28 | 50 | 0.56 | Under-funded |
| 8 | Alpha-Synuclein Immunotherapy | $85 | 45 | 1.89 | Over-funded |
| 9 | LRRK2 Inhibitors | $75 | 44 | 1.70 | Over-funded |
| 10 | GBA Gene Therapy | $22 | 34 | 0.65 | Under-funded |
| 11 | AAV Gene Therapy | $48 | 44 | 1.09 | Balanced |
| 12 | Cell Replacement (iPSC) | $35 | 40 | 0.88 | Balanced |
| 13 | Mitophagy Activators (PINK1/Parkin) | $15 | 31 | 0.48 | Under-funded |
| 14 | Iron Chelators | $8 | 39 | 0.21 | Under-funded |
| 15 | Calcium Channel Blockers | $6 | 39 | 0.15 | Under-funded |
| 16 | Microbiome Modulation | $12 | 36 | 0.33 | Under-funded |
| 17 | Neuroinflammation Inhibitors | $65 | 41 | 1.59 | Over-funded |
| 18 | Sigma-1 Agonists | $5 | 38 | 0.13 | Under-funded |
| 19 | Sleep Optimization | $4 | 49 | 0.08 | Under-funded |
| 20 | Focused Ultrasound | $15 | 42 | 0.36 | Under-funded |
Ratio: 1.89
Despite significant investment, alpha-synuclein immunotherapy trials (cinpanemab, prasinezumab) have shown mixed results. The Phase 2 SPARK trial of prasinezumab missed primary endpoints.
Why the disconnect?
Recommendation: Maintain funding but rebalance toward combination approaches and better patient stratification biomarkers.
Ratio: 1.70
Multiple LRRK2 inhibitors in development (denileukin, BIIB122), but questions remain about:
Recommendation: Pivot funding toward understanding LRRK2 biology in sporadic PD and combination with other mechanisms.
Ratio: 1.59
Masitinib and other neuroinflammation approaches have shown modest signals[^5], but:
Recommendation: Fund biomarker-driven trials targeting specific inflammatory pathways rather than broad approaches.
Ratio: 0.08 — Most under-funded
Remarkably underfunded given:
Recommendation: Increase 10x to ~$40M for RBD→PD prevention trials.
Ratio: 0.15
Isradipine showed preclinical promise but failed in clinical trials. However:
Recommendation: Fund precision medicine approach with genetic stratification.
Ratio: 0.32
Highest evidence score among non-pharmacological approaches, yet:
Recommendation: Double to $36M for implementation research and virtual delivery.
Ratio: 0.76
The gold standard treatment is dramatically underfunded:
Recommendation: Increase to $75M for delivery optimization and early intervention studies.
Ratio: 0.48
Despite low current score (early-stage), this addresses root cause:
Recommendation: Increase to $35M given high ceiling potential.
The PD Knowledge Gaps Ranked identifies key research priorities:
| Gap Area | Priority Score | Current Funding | Alignment |
|---|---|---|---|
| Alpha-synuclein triggers | 30 | $85M (α-syn immunotherapy) | Misaligned - too much on therapy, not enough on biology |
| Selective vulnerability | 30 | $12M | Misaligned - critical gap underfunded |
| LRRK2 non-manifesting carriers | 30 | $75M (inhibitors) | Misaligned - more on inhibition than understanding |
| Gut-brain axis | 30 | $12M (microbiome) | Underfunded - high priority, low funding |
| Disease subtypes | 28 | $8M | Underfunded - critical for precision medicine |
The strongest funding倾斜 toward "curative" approaches (immunotherapy, gene therapy) that address root cause but score lower on evidence. Meanwhile, proven symptomatic treatments with high evidence scores are underfunded.
This reflects:
A more rational funding portfolio would: